These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

186 related items for PubMed ID: 17178476

  • 1. Using Caenorhabditis elegans models of neurodegenerative disease to identify neuroprotective strategies.
    Kraemer B, Schellenberg GD.
    Int Rev Neurobiol; 2007; 77():219-46. PubMed ID: 17178476
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Clinical and experimental neuroprotection in neurodegenerative diseases is a therapeutic option for the future of amyotrophic lateral sclerosis (ALS). Preface.
    Ludolph AC, Drory VE.
    J Neurol; 2000 Dec; 247 Suppl 6():VI/1. PubMed ID: 19714407
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Nortriptyline delays disease onset in models of chronic neurodegeneration.
    Wang H, Guan Y, Wang X, Smith K, Cormier K, Zhu S, Stavrovskaya IG, Huo C, Ferrante RJ, Kristal BS, Friedlander RM.
    Eur J Neurosci; 2007 Aug; 26(3):633-41. PubMed ID: 17686041
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Invertebrate disease models in neurotherapeutic discovery.
    Westlund B, Stilwell G, Sluder A.
    Curr Opin Drug Discov Devel; 2004 Mar; 7(2):169-78. PubMed ID: 15603250
    [Abstract] [Full Text] [Related]

  • 9. Caenorhabditis elegans: a useful tool to decipher neurodegenerative pathways.
    Johnson JR, Jenn RC, Barclay JW, Burgoyne RD, Morgan A.
    Biochem Soc Trans; 2010 Apr; 38(2):559-63. PubMed ID: 20298221
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. The adult human brain in preclinical drug development.
    Dragunow M.
    Nat Rev Drug Discov; 2008 Aug; 7(8):659-66. PubMed ID: 18617887
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Metallothionein provides ubiquinone-mediated neuroprotection in Parkinson's disease.
    Ebadi M, Sharma S, Muralikrishnan D, Shavali S, Eken J, Sangchot P, Chetsawang B, Brekke L.
    Proc West Pharmacol Soc; 2002 Aug; 45():36-8. PubMed ID: 12434520
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Invertebrate animal models of diseases as screening tools in drug discovery.
    Ségalat L.
    ACS Chem Biol; 2007 Apr 24; 2(4):231-6. PubMed ID: 17455900
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Melatonin and the aging brain.
    Bondy SC, Sharman EH.
    Neurochem Int; 2007 Mar 24; 50(4):571-80. PubMed ID: 17276551
    [Abstract] [Full Text] [Related]

  • 19. Magnesium therapy and recovery of function in experimental models of brain injury and neurodegenerative disease.
    Hoane MR.
    Clin Calcium; 2004 Aug 24; 14(8):65-70. PubMed ID: 15577099
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.